219 related articles for article (PubMed ID: 32492723)
1. Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants.
Bavalia R; Middeldorp S; Weisser G; Espinola-Klein C
Thromb Haemost; 2020 Jun; 120(6):899-911. PubMed ID: 32492723
[TBL] [Abstract][Full Text] [Related]
2. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
[TBL] [Abstract][Full Text] [Related]
3. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
Finks SW; Trujillo TC; Dobesh PP
Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821
[TBL] [Abstract][Full Text] [Related]
4. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
van Es N; Coppens M; Schulman S; Middeldorp S; Büller HR
Blood; 2014 Sep; 124(12):1968-75. PubMed ID: 24963045
[TBL] [Abstract][Full Text] [Related]
5. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
Vedovati MC; Giustozzi M; Becattini C
Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513
[TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Voigtlaender M; Langer F
Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
Weitz JI; Jaffer IH
Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
[TBL] [Abstract][Full Text] [Related]
9. Drug Treatment of Venous Thromboembolism in the Elderly.
Boey JP; Gallus A
Drugs Aging; 2016 Jul; 33(7):475-90. PubMed ID: 27255713
[TBL] [Abstract][Full Text] [Related]
10. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations.
van Es N; Büller HR
Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711
[TBL] [Abstract][Full Text] [Related]
11. DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Meta-Analysis.
Chaudhary R; Pagali S; Garg J; Murad MH; Wysokinski WE; McBane RD
J Am Geriatr Soc; 2020 Sep; 68(9):2021-2026. PubMed ID: 32441334
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
13. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
Leung TS; Law EH
Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
[TBL] [Abstract][Full Text] [Related]
15. Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.
Goldhaber SZ; Ageno W; Casella IB; Chee KH; Schellong S; Singer DE; Desch M; Reilly PA; Donado E; Tang W; Voccia I; Schulman S
Am J Med; 2020 Aug; 133(8):936-945. PubMed ID: 32325043
[TBL] [Abstract][Full Text] [Related]
16. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
17. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis.
Alhousani M; Malik SU; Abu-Hashyeh A; Poznanski NJ; Al-Hasan S; Roth DF; Alsharedi M; Mustafa B
Thromb Res; 2021 Feb; 198():103-114. PubMed ID: 33310644
[TBL] [Abstract][Full Text] [Related]
18. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment.
Burnett AE; Mahan CE; Vazquez SR; Oertel LB; Garcia DA; Ansell J
J Thromb Thrombolysis; 2016 Jan; 41(1):206-32. PubMed ID: 26780747
[TBL] [Abstract][Full Text] [Related]
19. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review.
Gómez-Outes A; Lecumberri R; Suárez-Gea ML; Terleira-Fernández AI; Monreal M; Vargas-Castrillón E
J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):490-500. PubMed ID: 25802423
[TBL] [Abstract][Full Text] [Related]
20. Just DOAC: Use of direct-acting oral anticoagulants in pediatrics.
Mills K; Hill C; King M; Pauley JL; Cober MP; Fenn NE; Omecene NE; Smith T; Sierra CM
Am J Health Syst Pharm; 2023 Mar; 80(7):412-422. PubMed ID: 36610740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
